Investors Catching Stocks Unum Group(NYSE:UNM): Immunomedics, Inc.(NASDAQ:IMMU)

0
7

Unum Group (UNM) will report its next earnings on Oct 24 AMC. The company reported the earnings of $1.37/Share in the last quarter where the estimated EPS by analysts was $1.29/share. The difference between the expected and actual EPS was $0.08/share, which represents an Earnings surprise of 6.2%.

Many analysts are providing their Estimated Earnings analysis for Unum Group and for the current quarter 15 analysts have projected that the stock could give an Average Earnings estimate of $1.31/share. These analysts have also projected a Low Estimate of $1.28/share and a High Estimate of $1.36/share.

In case of Revenue Estimates, 5 analysts have provided their consensus Average Revenue Estimates for Unum Group as 2.91 Billion. According to these analysts, the Low Revenue Estimate for Unum Group is 2.89 Billion and the High Revenue Estimate is 2.94 Billion. The company had Year Ago Sales of 2.83 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for UNM to be 16.8%. They are projecting Next Quarter growth of 6.45%. For the next 5 years, Unum Group is expecting Growth of 5.42% per annum, whereas in the past 5 years the growth was 21.68% per annum.

Some buy side analysts are also providing their Analysis on Unum Group, where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 3 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Unum Group might touch $55 high while the Average Price Target and Low price Target is $43.54 and $34 respectively.

Unum Group closed its last trading session at $38.15 with the loss of -1.15%. The Market Capitalization of the company stands at 8.25 Billion. The Company has 52-week high of $58.73 and 52-week low of $33.27. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 2.77% where SMA50 and SMA200 are 0.36% and -9.54% respectively. The Company Touched its 52-Week High on 01/12/18 and 52-Week Low on 10/25/18.

The Relative Volume of the company is 0.97 and Average Volume (3 months) is 2.35 million. The company’s P/E (price to earnings) ratio is 16.63 and Forward P/E ratio of 6.88.

The company shows its Return on Assets (ROA) value of 0.9%. The Return on Equity (ROE) value stands at 5.8%. While it’s Return on Investment (ROI) value is 9%.

While looking at the Stock’s Performance, Unum Group currently shows a Weekly Performance of 1.45%, where Monthly Performance is 2.17%, Quarterly performance is 7.71%, 6 Months performance is -0.45% and yearly performance percentage is -28.21%. Year to Date performance value (YTD perf) value is -31.3%. The Stock currently has a Weekly Volatility of 2.25% and Monthly Volatility of 3.29%.

Immunomedics, Inc. (IMMU) will report its next earnings on Nov 07 AMC. The company reported the earnings of $-0.34/Share in the last quarter where the estimated EPS by analysts was $-0.28/share. The difference between the expected and actual EPS was $-0.06/share, which represents an Earnings surprise of -21.4%.

Many analysts are providing their Estimated Earnings analysis for Immunomedics, Inc. and for the current quarter 7 analysts have projected that the stock could give an Average Earnings estimate of $-0.33/share. These analysts have also projected a Low Estimate of $-0.44/share and a High Estimate of $-0.27/share.

These analysts also forecasted Growth Estimates for the Current Quarter for IMMU to be -63.2%. They are projecting Next Quarter growth of -78.57%. For the next 5 years, Immunomedics, Inc. is expecting Growth of 26.3% per annum, whereas in the past 5 years the growth was -11.65% per annum.

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Immunomedics, Inc. might touch $55 high while the Average Price Target and Low price Target is $37.38 and $30 respectively.

Immunomedics, Inc. closed its last trading session at $22.02 with the loss of -2.52%. The Market Capitalization of the company stands at 4 Billion. The Company has 52-week high of $27.33 and 52-week low of $8.68. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -5.38% where SMA50 and SMA200 are -4.71% and 3.9% respectively. The Company Touched its 52-Week High on 07/18/18 and 52-Week Low on 12/05/17.

The Relative Volume of the company is 1.33 and Average Volume (3 months) is 1.72 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -80.9%. The Return on Equity (ROE) value stands at -258.5%. While it’s Return on Investment (ROI) value is -33.6%.

While looking at the Stock’s Performance, Immunomedics, Inc. currently shows a Weekly Performance of -12.46%, where Monthly Performance is 4.15%, Quarterly performance is -5.61%, 6 Months performance is 14.24% and yearly performance percentage is 105.6%. Year to Date performance value (YTD perf) value is 32.83%. The Stock currently has a Weekly Volatility of 6.16% and Monthly Volatility of 5.86%.

SHARE